Some patients with psoriatic arthritis are refractive to one biologic therapy but not to others, and a strategy for selecting the right therapy for each patient is needed. The findings of a new study highlight the potential benefit of stratifying patients by their immunophenotype to select the optimal biologic to use.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nograles, K. E., Brasington, R. D. & Bowcock, A. M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat. Clin. Pract. Rheumatol. 5, 83–91 (2009).
Miyagawa, I. et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/key069 (2018).
Diani, M., Altomare, G. & Reali, E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun. Rev. 14, 286–292 (2015).
Crome, S. Q., Wang, A. Y. & Levings, M. K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 159, 109–119 (2010).
Kestens, L. et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin. Exp. Immunol. 95, 436–441 (1994).
Langley, R. G. et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N. Engl. J. Med. 371, 326–338 (2014).
Theander, E. et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann. Rheum. Dis. 73, 407–413 (2014).
Mease, P. J. et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open 4, e000638 (2018).
H.A.-M. is funded as a National Institute for Health Research clinical lecturer and Oxford-UCB prize fellow. L.C.C is funded by a National Institute for Health Research Clinician Scientist award. The work of the authors is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed in this commentary are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health.
The authors declare no competing interests.
About this article
Cite this article
Al-Mossawi, H., Coates, L.C. Personalized medicine — a new reality in psoriatic arthritis?. Nat Rev Rheumatol 14, 449–451 (2018). https://doi.org/10.1038/s41584-018-0043-3
This article is cited by
Current Rheumatology Reports (2019)
Drugs & Aging (2019)